UTHR:NGS-United Therapeutics Corporation (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 314.84

Change

+7.19 (+2.34)%

Market Cap

USD 5.48B

Volume

0.49M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.63 (+0.51%)

USD 11.63B
VTRS Viatris Inc

+0.24 (+2.79%)

USD 9.73B
LNTH Lantheus Holdings Inc

+1.34 (+1.81%)

USD 7.11B
ALKS Alkermes Plc

+0.35 (+1.17%)

USD 4.74B
ALVO Alvotech

-0.04 (-0.36%)

USD 2.92B
HCM HUTCHMED DRC

+0.63 (+4.76%)

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

+0.32 (+3.03%)

USD 2.09B
KNSA Kiniksa Pharmaceuticals Ltd

-0.08 (-0.29%)

USD 1.92B
SUPN Supernus Pharmaceuticals Inc

-0.47 (-1.46%)

USD 1.80B
EVO Evotec SE ADR

-0.18 (-4.55%)

USD 1.68B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

N/A

USD 0.46B
SANE 4.17 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.36 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.48 % 0.00 %

+0.98 (+0%)

USD 0.04B
SRHQ Elevation Series Trust - .. 2.36 % 0.00 %

+0.01 (+0%)

N/A
FHH:CA First Trust AlphaDEX US H.. 2.23 % 0.77 %

-0.20 (0%)

CAD 0.01B
FXH First Trust Health Care A.. 2.22 % 0.63 %

+1.09 (+0%)

USD 0.90B
DSMC ETF Series Solutions 1.77 % 0.00 %

+0.03 (+0%)

N/A
THNZ:XETRA 0.85 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.82 % 0.00 %

+0.07 (+0%)

N/A
JMEE JPMorgan Market Expansion.. 0.62 % 0.00 %

+0.20 (+0%)

USD 1.75B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+2.27 (+0%)

N/A
GURU Global X Guru Index ETF 0.00 % 0.75 %

+0.15 (+0%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.56 (0%)

USD 0.05B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+3.31 (+0%)

USD 0.54B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+1.03 (+0%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+8.05 (+0%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.14 (+0%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.69 (+0%)

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.48 (0%)

N/A
QDVC:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.10 (0%)

N/A
AFMC First Trust Active Factor.. 0.00 % 0.00 %

+0.07 (+0%)

USD 0.06B
BIOT 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.77% 52% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.77% 52% F 39% F
Trailing 12 Months  
Capital Gain 16.98% 73% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.98% 73% C 73% C
Trailing 5 Years  
Capital Gain 173.77% 93% A 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.77% 93% A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 24.50% 65% D 81% B-
Dividend Return 24.50% 65% D 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.51% 85% B 62% D
Risk Adjusted Return 85.93% 98% N/A 94% A
Market Capitalization 5.48B 100% F 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.80 66% 65%
Price/Book Ratio 2.00 48% 46%
Price / Cash Flow Ratio 10.24 29% 28%
Price/Free Cash Flow Ratio 6.25 46% 46%
Management Effectiveness  
Return on Equity 19.94% 89% 90%
Return on Invested Capital 15.39% 86% 83%
Return on Assets 12.97% 96% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.